Medoquip

Ropinirole, the active ingredient in Medoquip, is a dopamine agonist presented as an oral tablet for oral use. It is used to manage symptoms of Parkinson's disease and restless legs syndrome in adult patients. GNH USA supplies Medoquip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medoquip (ropinirole) acts on dopaminergic pathways to improve motor control and reduce uncomfortable sensations. - Parkinson's disease: improves motor function, reduces rigidity and tremor. - Restless legs syndrome: decreases leg discomfort and the urge to move, especially at night. - Parkinson's disease (off periods): shortens the duration of off‑time between levodopa doses.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: feeling light‑headed, especially when standing. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Impulse control disorders: compulsive gambling, shopping or eating. - Severe hypotension: marked drop in blood pressure causing faintness. - Depression or suicidal thoughts: mood changes requiring immediate medical attention.

Before initiating therapy, consider the following precautions. - Dose titration: start with a low dose and increase gradually under medical supervision. - Renal impairment: adjust dose in patients with reduced kidney function. - Cardiovascular disease: monitor blood pressure and heart rate regularly. - Psychiatric history: assess for depression, hallucinations or impulse control issues. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and light.

Ropinirole may interact with several medicines. Major Interactions (Avoid): - MAO‑B inhibitors (e.g., selegiline): risk of hypertensive crisis. - CYP1A2 inhibitors (e.g., fluvoxamine): increase ropinirole plasma levels. - Antipsychotics (dopamine antagonists): reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure lowering effect. - Alcohol: may enhance sedation and dizziness. - Other dopamine agonists: cumulative dopaminergic activity may increase side‑effect risk.